News | April 14, 2025
Novartis to invest $23 billion on expansion of manufacturing and R&D facilities in US
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
Overall investment in the US facility is estimated around US$50 million
ANVIMO will be available in dosages of 240 mg and 480 mg
WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
Subscribe To Our Newsletter & Stay Updated
